415 Capital

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

Endovascular Engineering is a preclinical stage company focused on developing innovative mechanical thrombectomy solutions aimed at addressing peripheral vascular conditions. The company specializes in creating and implementing advanced clot removal technologies specifically designed for venous thromboembolism, which includes treatment for significant health issues such as pulmonary embolism and deep vein thrombosis. By equipping healthcare professionals with effective medical tools, Endovascular Engineering aims to enhance the management of these critical conditions and improve patient outcomes.

R3 Vascular specializes in developing and manufacturing innovative medical devices aimed at treating peripheral arterial disease. The company focuses on bioresorbable scaffold technology, specifically creating vascular scaffolds that incorporate a sirolimus coating known for its anti-inflammatory properties. This technology is designed to balance strength and flexibility, enhancing treatment outcomes for patients. One of their notable products, the magnitude BRS device, is recognized as the thinnest bioresorbable scaffold tested in clinical settings, featuring a strut thickness of just 98 microns across various diameters. Through its proprietary polymer technologies, R3 Vascular aims to improve the management of peripheral arterial diseases, particularly in challenging areas such as below the knee.

Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

TRiCares is a medical device company focused on creating a catheter-based valve replacement system aimed at the minimally invasive treatment of tricuspid valve regurgitation. The company's innovative medical devices are designed to address tricuspid insufficiency with a simplified approach that enhances usability. By prioritizing anatomical conformation, TRiCares seeks to provide patients with effective and lasting solutions for tricuspid valve issues, ultimately improving their health outcomes.

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.

Distalmotion is a medical device company headquartered in Lausanne, Switzerland, focused on simplifying robotic surgery to enhance patient access to minimally invasive care in general surgery, gynecology, and urology. The company has developed a surgical robot named Dexter, which is designed and manufactured in Switzerland. Dexter merges the advantages of traditional laparoscopy with robotic capabilities, offering an innovative, on-demand approach to surgical procedures. This technology allows healthcare professionals to perform dissection and suturing in the abdominal cavity, streamlining the surgical process while maintaining affordability. Distalmotion aims to set a new standard of care by improving surgical outcomes and accessibility through its advanced robotic solutions.

Aktiia focuses on continuous and accurate blood pressure monitoring to address the global challenge of hypertension, which affects over 1.4 billion people and contributes to more than 18 million deaths annually. Founded on two decades of research, Aktiia's innovative technology combines optical sensors with clinically validated software algorithms to provide personalized, medical-grade blood pressure and heart rate data. This continuous monitoring enables individuals, researchers, and clinicians to gain deeper insights into hypertension, fostering more effective and personalized patient care. By improving accessibility and accuracy in blood pressure management, Aktiia aims to change the approach to this critical health issue, ultimately enhancing the understanding and treatment of high blood pressure.

Cardiac Success specializes in developing medical devices aimed at enhancing cardiac function for patients suffering from heart failure and functional mitral regurgitation. The company's primary product, the V-sling device, is a transcatheter ventricular repair solution designed specifically for individuals with Reduced Ejection Fraction. This innovative device is based on a proven surgical technique that approximates the papillary muscle, providing significant relief from severe heart conditions. By focusing on advanced treatment options, Cardiac Success aims to improve the quality of life for patients facing critical cardiac challenges.

CorFlow Therapeutics is a medtech startup focused on developing innovative technologies for the diagnosis and treatment of microvascular obstructions (MVO) in patients experiencing severe heart attacks. The company has created a controlled flow infusion system that measures the degree of MVO through a proprietary concept known as dynamic microvascular resistance. This system provides interventional cardiologists with critical data that can be compared to post-procedure contrast-enhanced magnetic resonance imaging. By enabling accurate diagnosis and treatment of MVO, CorFlow aims to reduce both short- and long-term complications in heart attack patients, addressing significant unmet medical needs in cardiovascular care.

Moray Medical specializes in developing advanced robotic delivery systems for structural heart therapies, particularly focusing on edge-to-edge valve leaflet repair for patients with leaky heart valves. The company aims to enhance the quality of life for individuals suffering from this condition by offering innovative solutions that enable cardiologists to perform mitral valve clip therapies more safely and cost-effectively. Moray Medical's technology features a compact, reusable fluid-drive system that allows precise movement of flexible delivery catheters, facilitated by a digital interface akin to operating a computer cursor. This approach streamlines the treatment process, making life-saving heart valve therapies more accessible to a greater number of patients.

R3 Vascular specializes in developing and manufacturing innovative medical devices aimed at treating peripheral arterial disease. The company focuses on bioresorbable scaffold technology, specifically creating vascular scaffolds that incorporate a sirolimus coating known for its anti-inflammatory properties. This technology is designed to balance strength and flexibility, enhancing treatment outcomes for patients. One of their notable products, the magnitude BRS device, is recognized as the thinnest bioresorbable scaffold tested in clinical settings, featuring a strut thickness of just 98 microns across various diameters. Through its proprietary polymer technologies, R3 Vascular aims to improve the management of peripheral arterial diseases, particularly in challenging areas such as below the knee.

Supira Medical, Inc. is a medical device company that specializes in developing a percutaneous ventricular assist device (pVAD) aimed at high-risk patients undergoing interventional procedures. This innovative device provides temporary mechanical support to assist the heart's native pumping action, making it a critical solution for patients facing severe coronary artery disease or cardiogenic shock during coronary interventions. The company's technology is designed to facilitate recovery in patients who require urgent mechanical support, thereby enhancing their ability to undergo necessary medical procedures. Founded in 2012 and based in Campbell, California, Supira Medical was previously known as Lumenblation Medical, Inc. before rebranding in March 2016.